Wolverine Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Wolverine Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-22,800	Closed	-$67K	–	1741
2018 Q1	$67K	Sell	22,800 -79,800	-78%	-$218K	﹤0.01%	1264
2017 Q4	$281K	Sell	102,600 -18,400	-15%	-$56.5K	﹤0.01%	1024
2017 Q3	$410K	Buy	121,000 +91,900	+316%	+$256K	﹤0.01%	870
2017 Q2	$71K	Buy	29,100 +5,000	+21%	+$11.5K	﹤0.01%	1082
2017 Q1	$54K	Buy	24,100 +9,100	+61%	+$20.1K	﹤0.01%	1012
2016 Q4	$31K	Sell	15,000 -186,300	-93%	-$520K	﹤0.01%	1055
2016 Q3	$674K	Sell	201,300 -3,200	-2%	-$10.2K	0.01%	646
2016 Q2	$642K	Buy	204,500 +202,810	+12,001%	+$676K	0.01%	653
2016 Q1	$52K	Sell	1,690 -764	-31%	-$2.38K	﹤0.01%	857
2015 Q4	$59K	Buy	2,454 +2,109	+611%	+$8.83K	﹤0.01%	1111
2015 Q3	$8K	Buy	+345	New	+$1.98K	﹤0.01%	1593
2013 Q4	–	Sell	-331	Closed	-$2K	–	3189
2013 Q3	$2K	Sell	331 -477	-59%	-$3.83K	﹤0.01%	2569
2013 Q2	$11K	Buy	+808	New	+$6.3K	﹤0.01%	2210

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wolverine Asset Management's PDLI Position: Q3 2020 in Review

Wolverine Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 1,688 shares — an estimated $4K sold.

Wolverine Asset Management first reported a position in PDLI in Q1 2020 and held it in 2 quarters. The position peaked at $4K in Q2 2020. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

Wolverine Asset Management reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
Wolverine Asset Management sold 1,688 PDL BioPharma, Inc. shares in Q3 2020, an estimated $4K.
Wolverine Asset Management first reported a position in PDL BioPharma, Inc. in Q1 2020 and held it in 2 quarters.
Wolverine Asset Management's PDL BioPharma, Inc. position peaked at $4K in Q2 2020.
132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on Wolverine Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.